ADOCIA to Deliver Oral Presentations on AdoShell® and AdoGel® at EASD Annual Meeting
The 60th annual congress of the EASD (
AdoShell® Islets
- Title: ADO12, a non-fibrotic immunoprotective hydrogel containing human islets shows efficient and sustained in vivo functionality for clinical use
-
Day and Time:
Friday, September 13, 2024 -11:00 -11:15 a.m. - Session: Protection in Islet Transplantation (OP-37; 219)
- Room: Madrid Hall
-
Authors:
Anne-Lise Gaffuri ,Xavier Gaume ,Romain Besnard ,Julie Brun ,Camille Gautier , Ouardane Jouannot,Nicolas Laurent ,Rosy Eloy , Karim Bouzakri,François Pattou ,Olivier Soula - Links: More details, including the abstract, are available on the EASD website.
About AdoShell® Islets:
AdoShell® Islets is a new immunoprotective hydrogel encapsulating islets of Langerhans. This permeable hydrogel allows the diffusion of insulin and glucose while preventing the invasion of antibodies and immune cells. This implantable device, which is fully retrievable by laparoscopy, has the potential to enable islet transplantation without the need for immunosuppression, offering an unprecedented solution for curing people with diabetes.
AdoShell® Islets have shown sustained survival and functionality of human islets in vitro for over 4 months. This long-term survival has been confirmed in vivo in immunodeficient mice, with a stable insulin or C-peptide secretion over 3 months, absence of fibrotic encapsulation and survival of functional islets.
AdoGel® Sema
- Title: Development of a once-a-month formulation of semaglutide from an innovative injectable and biodegradable hydrogel
-
Day and time:
Tuesday, September 10, 2024 - 14:00 -14:15 - Session: Hot of the press novel incretins (B. SO 062 - oral 746)
- Room: station 11
-
Authors:
Romain Besnard ,Audrey Marechal , Claire Mégret,Sana Hakim ,Jenny Erales ,Ulysse Naessens , Maud Fumex,Martin Gaudier ,Olivier Soula , You-Ping Chan , Emmanuel Dauty - Links: More details, including the abstract, are available on the EASD website.
About AdoGel®:
Designed to enable the long-acting delivery of peptides, AdoGel® is currently being studied for semaglutide (GLP‑1). The unique AdoGel® technology aims to offer monthly or even quarterly peptide injections, replacing the weekly injections currently on the market.
The results showed that a regular release of semaglutide over one month associated with limited early release is achievable. This could be a real benefit for treatment efficacy and safety as well as patient compliance by limiting the injection frequencies and reducing side effects
About EASD
EASD 2024 is the 60th annual congress of the
The congress brings together key opinion leaders, corporate executives, scientists, physicians, researchers, caregivers and students interested in diabetes and related topics. The aim of the EASD Annual Congress is to encourage excellence in diabetes management through research and education.
About
The Company has a broad portfolio of drug candidates based on four proprietary technology platforms: 1) The BioChaperone® technology for the development of new generation insulins and products combining different hormones; 2) AdOral®, an oral peptide delivery technology; 3) AdoShell®, an immunoprotective biomaterial for cell transplantation, with an initial application in pancreatic cells transplantation; and 4) AdoGel®, a long-acting drug delivery platform.
Disclaimer
This press release contains certain forward-looking statements concerning
The forward-looking statements contained in this press release are also subject to risks not yet known to
View source version on businesswire.com: https://www.businesswire.com/news/home/20240829633824/en/
CEO
contactinvestisseurs@adocia.com
+33 (0)4 72 610 610
www.adocia.com
Ulysse Communication
adocia@ulysse-communication.com
+ 33 (0)6 87 88 47 26
Source: